Furthermore, in a study performed by Morano et al. [18], treatment of patients with type 2 diabetes with liraglutide (1.2 mg/day for 12 weeks) or exenatide, another GLP-1 analogue, resulted in a reduction of epicardial fat volume as assessed by ultrasonography. Here, GCG is linked to type 2 diabetes mellitus.